Samuel Strober

Samuel Strober (born c. 1940) is a biomedical researcher and inventor best known for his work on the elimination of the need for life long immune suppressive drugs in organ transplant patients. Strober received his bachelor's degree from Columbia College[1] in 1961, and his MD from the Harvard Medical School [2] in 1966. He also studied at Massachusetts General[3] and Stanford University Hospitals[4] and the Sir William Dunn School of Pathology[5] at Oxford University.

He was chief of the Division of Immunology and Rheumatology[6] at the Stanford University School of Medicine (1979–1997); a co-founder of a biotechnology company, Dendreon, that developed the first FDA approved cancer vaccination; President of the Clinical Immunology Society (1996);[7] and Chairman of the Board of Directors of the La Jolla Institute for Allergy and Immunology.[8] He has a son, young William Strober, who is currently in medical school at the University of Pittsburgh School of medicine.